ChemoCentryx (NASDAQ:CCXI) Receiving Somewhat Favorable News Coverage, Study Finds

Press coverage about ChemoCentryx (NASDAQ:CCXI) has trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ChemoCentryx earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.4597542705055 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

CCXI has been the subject of several research analyst reports. BidaskClub raised ChemoCentryx from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 3rd. JPMorgan Chase reissued an “overweight” rating and set a $16.00 price target (up from $13.00) on shares of ChemoCentryx in a research report on Tuesday, March 13th. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $14.00 target price on the stock in a research report on Wednesday, March 14th. Finally, ValuEngine raised ChemoCentryx from a “hold” rating to a “buy” rating in a research report on Wednesday, March 14th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $15.00.

Shares of CCXI traded down $0.14 during trading hours on Thursday, hitting $12.66. 160,002 shares of the company were exchanged, compared to its average volume of 305,971. ChemoCentryx has a 52 week low of $5.42 and a 52 week high of $15.08. The company has a market cap of $590.96, a PE ratio of 35.17 and a beta of 1.58. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.46 and a current ratio of 5.46.

ChemoCentryx (NASDAQ:CCXI) last announced its earnings results on Friday, March 9th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $1.02. The business had revenue of $56.30 million for the quarter, compared to the consensus estimate of $9.03 million. research analysts predict that ChemoCentryx will post -1.18 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “ChemoCentryx (NASDAQ:CCXI) Receiving Somewhat Favorable News Coverage, Study Finds” was posted by BBNS and is the sole property of of BBNS. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://baseballnewssource.com/2018/04/05/chemocentryx-ccxi-earns-media-sentiment-score-of-0-20/2028016.html.

ChemoCentryx Company Profile

ChemoCentryx, Inc is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact.

Insider Buying and Selling by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.